Rhythm Pharmaceuticals, Inc.
RYTM
주식 순위
#2960
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial... Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
주가
$90.58
마지막 동기화: 2026-10-20
시가총액
$6.24B
변동 (1일)
2.66%
변동 (1년)
-15.46%
국가
US
거래 Rhythm Pharmaceuticals, Inc. (RYTM)
카테고리
Healthcare
Rhythm Pharmaceuticals, Inc. (RYTM)의 매출
Jun 2026 기준 매출 TTM: $239.92M
Rhythm Pharmaceuticals, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $239.92M입니다. 2023년에 회사는 $77.43M의 수익을 올렸으며 이는 2022년의 $23.64M 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Rhythm Pharmaceuticals, Inc.의 수익 기록 (2012 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $239.92M | 84.37% |
| 2024 | $130.13M | 68.06% |
| 2023 | $77.43M | 227.56% |
| 2022 | $23.64M | 649.46% |
| 2021 | $3.15M | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $12.62B | 5,161.92% |
US
|
|
| $2.23B | 828.65% |
US
|
|
| $15.74B | 6,462.38% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 2,409.73% |
NL
|
